San Francisco startup Framework Therapeutics is also working on an oral, the moment-daily GLP-one drug identified as GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June any time a mid-stage examine confirmed average weight loss of around six% and it designs to get started on An additional mid-phase trial to the top of this yr—tha… Read More